Eintrag weiter verarbeiten
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study
Gespeichert in:
| Zeitschriftentitel: | Addiction |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| In: | Addiction, 109, 2014, 2, S. 262-272 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. |
|---|---|
| author |
van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. |
| spellingShingle |
van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. Addiction Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study Psychiatry and Mental health Medicine (miscellaneous) |
| author_sort |
van emmerik‐van oortmerssen, katelijne |
| spelling |
van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. 0965-2140 1360-0443 Wiley Psychiatry and Mental health Medicine (miscellaneous) http://dx.doi.org/10.1111/add.12370 <jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To determine comorbidity patterns in treatment‐seeking substance use disorder (<jats:styled-content style="fixed-case">SUD</jats:styled-content>) patients with and without adult attention deficit hyperactivity disorder (<jats:styled-content style="fixed-case">ADHD</jats:styled-content>), with an emphasis on subgroups defined by <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtype, taking into account differences related to gender and primary substance of abuse.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Data were obtained from the cross‐sectional <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in Substance use disorder Prevalence (<jats:styled-content style="fixed-case">IASP</jats:styled-content>) study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Forty‐seven centres of <jats:styled-content style="fixed-case">SUD</jats:styled-content> treatment in 10 countries.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>A total of 1205 treatment‐seeking <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients.</jats:p></jats:sec><jats:sec><jats:title>Measurements</jats:title><jats:p>Structured diagnostic assessments were used for all disorders: presence of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> was assessed with the <jats:styled-content style="fixed-case">C</jats:styled-content>onners' <jats:styled-content style="fixed-case">A</jats:styled-content>dult <jats:styled-content style="fixed-case">ADHD D</jats:styled-content>iagnostic <jats:styled-content style="fixed-case">I</jats:styled-content>nterview for <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> (<jats:styled-content style="fixed-case">CAADID</jats:styled-content>), the presence of antisocial personality disorder (<jats:styled-content style="fixed-case">ASPD</jats:styled-content>), major depression (<jats:styled-content style="fixed-case">MD</jats:styled-content>) and (hypo)manic episode (<jats:styled-content style="fixed-case">HME</jats:styled-content>) was assessed with the <jats:styled-content style="fixed-case">M</jats:styled-content>ini <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">N</jats:styled-content>europsychiatric <jats:styled-content style="fixed-case">I</jats:styled-content>nterview‐<jats:styled-content style="fixed-case">P</jats:styled-content>lus (<jats:styled-content style="fixed-case">MINI P</jats:styled-content>lus), and the presence of borderline personality disorder (<jats:styled-content style="fixed-case">BPD</jats:styled-content>) was assessed with the Structured Clinical Interview for DSM‐IV Axis II (<jats:styled-content style="fixed-case">SCID II)</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>The prevalence of <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> adult <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in this <jats:styled-content style="fixed-case">SUD</jats:styled-content> sample was 13.9%. <jats:styled-content style="fixed-case">ASPD</jats:styled-content> [odds ratio (<jats:styled-content style="fixed-case">OR)</jats:styled-content> = 2.8, 95% confidence interval (<jats:styled-content style="fixed-case">CI</jats:styled-content>) = 1.8–4.2], <jats:styled-content style="fixed-case">BPD</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 7.0, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 3.1–15.6 for alcohol; <jats:styled-content style="fixed-case">OR</jats:styled-content> = 3.4, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 1.8–6.4 for drugs), <jats:styled-content style="fixed-case">MD</jats:styled-content> in patients with alcohol as primary substance of abuse (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.1, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–7.8) and <jats:styled-content style="fixed-case">HME</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.3, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–8.7) were all more prevalent in <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>+</jats:sup> compared with <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>−</jats:sup> patients (<jats:italic>P</jats:italic> < 0.001). These results also indicate increased levels of <jats:styled-content style="fixed-case">BPD</jats:styled-content> and <jats:styled-content style="fixed-case">MD</jats:styled-content> for alcohol compared with drugs as primary substance of abuse. Comorbidity patterns differed between <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtypes with increased <jats:styled-content style="fixed-case">MD</jats:styled-content> in the inattentive and combined subtype (<jats:italic>P</jats:italic> < 0.01), increased <jats:styled-content style="fixed-case">HME</jats:styled-content> and <jats:styled-content style="fixed-case">ASPD</jats:styled-content> in the hyperactive/impulsive (<jats:italic>P</jats:italic> < 0.01) and combined subtypes (<jats:italic>P</jats:italic> < 0.001) and increased <jats:styled-content style="fixed-case">BPD</jats:styled-content> in all subtypes (<jats:italic>P</jats:italic> < 0.001) compared with <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>. Seventy‐five per cent of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> patients had at least one additional comorbid disorder compared with 37% of <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Treatment‐seeking substance use disorder patients with attention deficit hyperactivity disorder are at a very high risk for additional externalizing disorders.</jats:p></jats:sec> Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>IASP</scp> study Addiction |
| doi_str_mv |
10.1111/add.12370 |
| facet_avail |
Online |
| finc_class_facet |
Medizin Psychologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hZGQuMTIzNzA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hZGQuMTIzNzA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2014 |
| imprint_str_mv |
Wiley, 2014 |
| issn |
0965-2140 1360-0443 |
| issn_str_mv |
0965-2140 1360-0443 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
vanemmerikvanoortmerssen2014psychiatriccomorbidityintreatmentseekingsubstanceusedisorderpatientswithandwithoutattentiondeficithyperactivitydisorderresultsoftheiaspstudy |
| publishDateSort |
2014 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Addiction |
| source_id |
49 |
| title |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_unstemmed |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_full |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_fullStr |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_full_unstemmed |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_short |
Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_sort |
psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>iasp</scp> study |
| topic |
Psychiatry and Mental health Medicine (miscellaneous) |
| url |
http://dx.doi.org/10.1111/add.12370 |
| publishDate |
2014 |
| physical |
262-272 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To determine comorbidity patterns in treatment‐seeking substance use disorder (<jats:styled-content style="fixed-case">SUD</jats:styled-content>) patients with and without adult attention deficit hyperactivity disorder (<jats:styled-content style="fixed-case">ADHD</jats:styled-content>), with an emphasis on subgroups defined by <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtype, taking into account differences related to gender and primary substance of abuse.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Data were obtained from the cross‐sectional <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in Substance use disorder Prevalence (<jats:styled-content style="fixed-case">IASP</jats:styled-content>) study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Forty‐seven centres of <jats:styled-content style="fixed-case">SUD</jats:styled-content> treatment in 10 countries.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>A total of 1205 treatment‐seeking <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients.</jats:p></jats:sec><jats:sec><jats:title>Measurements</jats:title><jats:p>Structured diagnostic assessments were used for all disorders: presence of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> was assessed with the <jats:styled-content style="fixed-case">C</jats:styled-content>onners' <jats:styled-content style="fixed-case">A</jats:styled-content>dult <jats:styled-content style="fixed-case">ADHD D</jats:styled-content>iagnostic <jats:styled-content style="fixed-case">I</jats:styled-content>nterview for <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> (<jats:styled-content style="fixed-case">CAADID</jats:styled-content>), the presence of antisocial personality disorder (<jats:styled-content style="fixed-case">ASPD</jats:styled-content>), major depression (<jats:styled-content style="fixed-case">MD</jats:styled-content>) and (hypo)manic episode (<jats:styled-content style="fixed-case">HME</jats:styled-content>) was assessed with the <jats:styled-content style="fixed-case">M</jats:styled-content>ini <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">N</jats:styled-content>europsychiatric <jats:styled-content style="fixed-case">I</jats:styled-content>nterview‐<jats:styled-content style="fixed-case">P</jats:styled-content>lus (<jats:styled-content style="fixed-case">MINI P</jats:styled-content>lus), and the presence of borderline personality disorder (<jats:styled-content style="fixed-case">BPD</jats:styled-content>) was assessed with the Structured Clinical Interview for DSM‐IV Axis II (<jats:styled-content style="fixed-case">SCID II)</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>The prevalence of <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> adult <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in this <jats:styled-content style="fixed-case">SUD</jats:styled-content> sample was 13.9%. <jats:styled-content style="fixed-case">ASPD</jats:styled-content> [odds ratio (<jats:styled-content style="fixed-case">OR)</jats:styled-content> = 2.8, 95% confidence interval (<jats:styled-content style="fixed-case">CI</jats:styled-content>) = 1.8–4.2], <jats:styled-content style="fixed-case">BPD</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 7.0, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 3.1–15.6 for alcohol; <jats:styled-content style="fixed-case">OR</jats:styled-content> = 3.4, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 1.8–6.4 for drugs), <jats:styled-content style="fixed-case">MD</jats:styled-content> in patients with alcohol as primary substance of abuse (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.1, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–7.8) and <jats:styled-content style="fixed-case">HME</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.3, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–8.7) were all more prevalent in <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>+</jats:sup> compared with <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>−</jats:sup> patients (<jats:italic>P</jats:italic> < 0.001). These results also indicate increased levels of <jats:styled-content style="fixed-case">BPD</jats:styled-content> and <jats:styled-content style="fixed-case">MD</jats:styled-content> for alcohol compared with drugs as primary substance of abuse. Comorbidity patterns differed between <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtypes with increased <jats:styled-content style="fixed-case">MD</jats:styled-content> in the inattentive and combined subtype (<jats:italic>P</jats:italic> < 0.01), increased <jats:styled-content style="fixed-case">HME</jats:styled-content> and <jats:styled-content style="fixed-case">ASPD</jats:styled-content> in the hyperactive/impulsive (<jats:italic>P</jats:italic> < 0.01) and combined subtypes (<jats:italic>P</jats:italic> < 0.001) and increased <jats:styled-content style="fixed-case">BPD</jats:styled-content> in all subtypes (<jats:italic>P</jats:italic> < 0.001) compared with <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>. Seventy‐five per cent of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> patients had at least one additional comorbid disorder compared with 37% of <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Treatment‐seeking substance use disorder patients with attention deficit hyperactivity disorder are at a very high risk for additional externalizing disorders.</jats:p></jats:sec> |
| container_issue |
2 |
| container_start_page |
262 |
| container_title |
Addiction |
| container_volume |
109 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340331957583883 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:02:18.155Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Psychiatric+comorbidity+in+treatment%E2%80%90seeking+substance+use+disorder+patients+with+and+without+attention+deficit+hyperactivity+disorder%3A+results+of+the+IASP+study&rft.date=2014-02-01&genre=article&issn=1360-0443&volume=109&issue=2&spage=262&epage=272&pages=262-272&jtitle=Addiction&atitle=Psychiatric+comorbidity+in+treatment%E2%80%90seeking+substance+use+disorder+patients+with+and+without+attention+deficit+hyperactivity+disorder%3A+results+of+the+%3Cscp%3EIASP%3C%2Fscp%3E+study&aulast=Schoevers&aufirst=Robert+A.&rft_id=info%3Adoi%2F10.1111%2Fadd.12370&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340331957583883 |
| author | van Emmerik‐van Oortmerssen, Katelijne, van de Glind, Geurt, Koeter, Maarten W. J., Allsop, Steve, Auriacombe, Marc, Barta, Csaba, Bu, Eli Torild H., Burren, Yuliya, Carpentier, Pieter‐Jan, Carruthers, Susan, Casas, Miguel, Demetrovics, Zsolt, Dom, Geert, Faraone, Stephen V., Fatseas, Melina, Franck, Johan, Johnson, Brian, Kapitány‐Fövény, Máté, Kaye, Sharlene, Konstenius, Maija, Levin, Frances R., Moggi, Franz, Møller, Merete, Ramos‐Quiroga, J. Antoni, Schillinger, Arild, Skutle, Arvid, Verspreet, Sofie, van den Brink, Wim, Schoevers, Robert A. |
| author_facet | van Emmerik‐van Oortmerssen, Katelijne, van de Glind, Geurt, Koeter, Maarten W. J., Allsop, Steve, Auriacombe, Marc, Barta, Csaba, Bu, Eli Torild H., Burren, Yuliya, Carpentier, Pieter‐Jan, Carruthers, Susan, Casas, Miguel, Demetrovics, Zsolt, Dom, Geert, Faraone, Stephen V., Fatseas, Melina, Franck, Johan, Johnson, Brian, Kapitány‐Fövény, Máté, Kaye, Sharlene, Konstenius, Maija, Levin, Frances R., Moggi, Franz, Møller, Merete, Ramos‐Quiroga, J. Antoni, Schillinger, Arild, Skutle, Arvid, Verspreet, Sofie, van den Brink, Wim, Schoevers, Robert A., van Emmerik‐van Oortmerssen, Katelijne, van de Glind, Geurt, Koeter, Maarten W. J., Allsop, Steve, Auriacombe, Marc, Barta, Csaba, Bu, Eli Torild H., Burren, Yuliya, Carpentier, Pieter‐Jan, Carruthers, Susan, Casas, Miguel, Demetrovics, Zsolt, Dom, Geert, Faraone, Stephen V., Fatseas, Melina, Franck, Johan, Johnson, Brian, Kapitány‐Fövény, Máté, Kaye, Sharlene, Konstenius, Maija, Levin, Frances R., Moggi, Franz, Møller, Merete, Ramos‐Quiroga, J. Antoni, Schillinger, Arild, Skutle, Arvid, Verspreet, Sofie, van den Brink, Wim, Schoevers, Robert A. |
| author_sort | van emmerik‐van oortmerssen, katelijne |
| container_issue | 2 |
| container_start_page | 262 |
| container_title | Addiction |
| container_volume | 109 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To determine comorbidity patterns in treatment‐seeking substance use disorder (<jats:styled-content style="fixed-case">SUD</jats:styled-content>) patients with and without adult attention deficit hyperactivity disorder (<jats:styled-content style="fixed-case">ADHD</jats:styled-content>), with an emphasis on subgroups defined by <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtype, taking into account differences related to gender and primary substance of abuse.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Data were obtained from the cross‐sectional <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in Substance use disorder Prevalence (<jats:styled-content style="fixed-case">IASP</jats:styled-content>) study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Forty‐seven centres of <jats:styled-content style="fixed-case">SUD</jats:styled-content> treatment in 10 countries.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>A total of 1205 treatment‐seeking <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients.</jats:p></jats:sec><jats:sec><jats:title>Measurements</jats:title><jats:p>Structured diagnostic assessments were used for all disorders: presence of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> was assessed with the <jats:styled-content style="fixed-case">C</jats:styled-content>onners' <jats:styled-content style="fixed-case">A</jats:styled-content>dult <jats:styled-content style="fixed-case">ADHD D</jats:styled-content>iagnostic <jats:styled-content style="fixed-case">I</jats:styled-content>nterview for <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> (<jats:styled-content style="fixed-case">CAADID</jats:styled-content>), the presence of antisocial personality disorder (<jats:styled-content style="fixed-case">ASPD</jats:styled-content>), major depression (<jats:styled-content style="fixed-case">MD</jats:styled-content>) and (hypo)manic episode (<jats:styled-content style="fixed-case">HME</jats:styled-content>) was assessed with the <jats:styled-content style="fixed-case">M</jats:styled-content>ini <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">N</jats:styled-content>europsychiatric <jats:styled-content style="fixed-case">I</jats:styled-content>nterview‐<jats:styled-content style="fixed-case">P</jats:styled-content>lus (<jats:styled-content style="fixed-case">MINI P</jats:styled-content>lus), and the presence of borderline personality disorder (<jats:styled-content style="fixed-case">BPD</jats:styled-content>) was assessed with the Structured Clinical Interview for DSM‐IV Axis II (<jats:styled-content style="fixed-case">SCID II)</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>The prevalence of <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> adult <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in this <jats:styled-content style="fixed-case">SUD</jats:styled-content> sample was 13.9%. <jats:styled-content style="fixed-case">ASPD</jats:styled-content> [odds ratio (<jats:styled-content style="fixed-case">OR)</jats:styled-content> = 2.8, 95% confidence interval (<jats:styled-content style="fixed-case">CI</jats:styled-content>) = 1.8–4.2], <jats:styled-content style="fixed-case">BPD</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 7.0, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 3.1–15.6 for alcohol; <jats:styled-content style="fixed-case">OR</jats:styled-content> = 3.4, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 1.8–6.4 for drugs), <jats:styled-content style="fixed-case">MD</jats:styled-content> in patients with alcohol as primary substance of abuse (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.1, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–7.8) and <jats:styled-content style="fixed-case">HME</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.3, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–8.7) were all more prevalent in <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>+</jats:sup> compared with <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>−</jats:sup> patients (<jats:italic>P</jats:italic> < 0.001). These results also indicate increased levels of <jats:styled-content style="fixed-case">BPD</jats:styled-content> and <jats:styled-content style="fixed-case">MD</jats:styled-content> for alcohol compared with drugs as primary substance of abuse. Comorbidity patterns differed between <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtypes with increased <jats:styled-content style="fixed-case">MD</jats:styled-content> in the inattentive and combined subtype (<jats:italic>P</jats:italic> < 0.01), increased <jats:styled-content style="fixed-case">HME</jats:styled-content> and <jats:styled-content style="fixed-case">ASPD</jats:styled-content> in the hyperactive/impulsive (<jats:italic>P</jats:italic> < 0.01) and combined subtypes (<jats:italic>P</jats:italic> < 0.001) and increased <jats:styled-content style="fixed-case">BPD</jats:styled-content> in all subtypes (<jats:italic>P</jats:italic> < 0.001) compared with <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>. Seventy‐five per cent of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> patients had at least one additional comorbid disorder compared with 37% of <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Treatment‐seeking substance use disorder patients with attention deficit hyperactivity disorder are at a very high risk for additional externalizing disorders.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/add.12370 |
| facet_avail | Online |
| finc_class_facet | Medizin, Psychologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hZGQuMTIzNzA |
| imprint | Wiley, 2014 |
| imprint_str_mv | Wiley, 2014 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0965-2140, 1360-0443 |
| issn_str_mv | 0965-2140, 1360-0443 |
| language | English |
| last_indexed | 2024-03-01T16:02:18.155Z |
| match_str | vanemmerikvanoortmerssen2014psychiatriccomorbidityintreatmentseekingsubstanceusedisorderpatientswithandwithoutattentiondeficithyperactivitydisorderresultsoftheiaspstudy |
| mega_collection | Wiley (CrossRef) |
| physical | 262-272 |
| publishDate | 2014 |
| publishDateSort | 2014 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Addiction |
| source_id | 49 |
| spelling | van Emmerik‐van Oortmerssen, Katelijne van de Glind, Geurt Koeter, Maarten W. J. Allsop, Steve Auriacombe, Marc Barta, Csaba Bu, Eli Torild H. Burren, Yuliya Carpentier, Pieter‐Jan Carruthers, Susan Casas, Miguel Demetrovics, Zsolt Dom, Geert Faraone, Stephen V. Fatseas, Melina Franck, Johan Johnson, Brian Kapitány‐Fövény, Máté Kaye, Sharlene Konstenius, Maija Levin, Frances R. Moggi, Franz Møller, Merete Ramos‐Quiroga, J. Antoni Schillinger, Arild Skutle, Arvid Verspreet, Sofie van den Brink, Wim Schoevers, Robert A. 0965-2140 1360-0443 Wiley Psychiatry and Mental health Medicine (miscellaneous) http://dx.doi.org/10.1111/add.12370 <jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>To determine comorbidity patterns in treatment‐seeking substance use disorder (<jats:styled-content style="fixed-case">SUD</jats:styled-content>) patients with and without adult attention deficit hyperactivity disorder (<jats:styled-content style="fixed-case">ADHD</jats:styled-content>), with an emphasis on subgroups defined by <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtype, taking into account differences related to gender and primary substance of abuse.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>Data were obtained from the cross‐sectional <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in Substance use disorder Prevalence (<jats:styled-content style="fixed-case">IASP</jats:styled-content>) study.</jats:p></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Forty‐seven centres of <jats:styled-content style="fixed-case">SUD</jats:styled-content> treatment in 10 countries.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>A total of 1205 treatment‐seeking <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients.</jats:p></jats:sec><jats:sec><jats:title>Measurements</jats:title><jats:p>Structured diagnostic assessments were used for all disorders: presence of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> was assessed with the <jats:styled-content style="fixed-case">C</jats:styled-content>onners' <jats:styled-content style="fixed-case">A</jats:styled-content>dult <jats:styled-content style="fixed-case">ADHD D</jats:styled-content>iagnostic <jats:styled-content style="fixed-case">I</jats:styled-content>nterview for <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> (<jats:styled-content style="fixed-case">CAADID</jats:styled-content>), the presence of antisocial personality disorder (<jats:styled-content style="fixed-case">ASPD</jats:styled-content>), major depression (<jats:styled-content style="fixed-case">MD</jats:styled-content>) and (hypo)manic episode (<jats:styled-content style="fixed-case">HME</jats:styled-content>) was assessed with the <jats:styled-content style="fixed-case">M</jats:styled-content>ini <jats:styled-content style="fixed-case">I</jats:styled-content>nternational <jats:styled-content style="fixed-case">N</jats:styled-content>europsychiatric <jats:styled-content style="fixed-case">I</jats:styled-content>nterview‐<jats:styled-content style="fixed-case">P</jats:styled-content>lus (<jats:styled-content style="fixed-case">MINI P</jats:styled-content>lus), and the presence of borderline personality disorder (<jats:styled-content style="fixed-case">BPD</jats:styled-content>) was assessed with the Structured Clinical Interview for DSM‐IV Axis II (<jats:styled-content style="fixed-case">SCID II)</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Findings</jats:title><jats:p>The prevalence of <jats:styled-content style="fixed-case">DSM‐IV</jats:styled-content> adult <jats:styled-content style="fixed-case">ADHD</jats:styled-content> in this <jats:styled-content style="fixed-case">SUD</jats:styled-content> sample was 13.9%. <jats:styled-content style="fixed-case">ASPD</jats:styled-content> [odds ratio (<jats:styled-content style="fixed-case">OR)</jats:styled-content> = 2.8, 95% confidence interval (<jats:styled-content style="fixed-case">CI</jats:styled-content>) = 1.8–4.2], <jats:styled-content style="fixed-case">BPD</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 7.0, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 3.1–15.6 for alcohol; <jats:styled-content style="fixed-case">OR</jats:styled-content> = 3.4, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 1.8–6.4 for drugs), <jats:styled-content style="fixed-case">MD</jats:styled-content> in patients with alcohol as primary substance of abuse (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.1, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–7.8) and <jats:styled-content style="fixed-case">HME</jats:styled-content> (<jats:styled-content style="fixed-case">OR</jats:styled-content> = 4.3, 95% <jats:styled-content style="fixed-case">CI</jats:styled-content> = 2.1–8.7) were all more prevalent in <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>+</jats:sup> compared with <jats:styled-content style="fixed-case">ADHD</jats:styled-content><jats:sup>−</jats:sup> patients (<jats:italic>P</jats:italic> < 0.001). These results also indicate increased levels of <jats:styled-content style="fixed-case">BPD</jats:styled-content> and <jats:styled-content style="fixed-case">MD</jats:styled-content> for alcohol compared with drugs as primary substance of abuse. Comorbidity patterns differed between <jats:styled-content style="fixed-case">ADHD</jats:styled-content> subtypes with increased <jats:styled-content style="fixed-case">MD</jats:styled-content> in the inattentive and combined subtype (<jats:italic>P</jats:italic> < 0.01), increased <jats:styled-content style="fixed-case">HME</jats:styled-content> and <jats:styled-content style="fixed-case">ASPD</jats:styled-content> in the hyperactive/impulsive (<jats:italic>P</jats:italic> < 0.01) and combined subtypes (<jats:italic>P</jats:italic> < 0.001) and increased <jats:styled-content style="fixed-case">BPD</jats:styled-content> in all subtypes (<jats:italic>P</jats:italic> < 0.001) compared with <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>. Seventy‐five per cent of <jats:styled-content style="fixed-case">ADHD</jats:styled-content> patients had at least one additional comorbid disorder compared with 37% of <jats:styled-content style="fixed-case">SUD</jats:styled-content> patients without <jats:styled-content style="fixed-case">ADHD</jats:styled-content>.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Treatment‐seeking substance use disorder patients with attention deficit hyperactivity disorder are at a very high risk for additional externalizing disorders.</jats:p></jats:sec> Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>IASP</scp> study Addiction |
| spellingShingle | van Emmerik‐van Oortmerssen, Katelijne, van de Glind, Geurt, Koeter, Maarten W. J., Allsop, Steve, Auriacombe, Marc, Barta, Csaba, Bu, Eli Torild H., Burren, Yuliya, Carpentier, Pieter‐Jan, Carruthers, Susan, Casas, Miguel, Demetrovics, Zsolt, Dom, Geert, Faraone, Stephen V., Fatseas, Melina, Franck, Johan, Johnson, Brian, Kapitány‐Fövény, Máté, Kaye, Sharlene, Konstenius, Maija, Levin, Frances R., Moggi, Franz, Møller, Merete, Ramos‐Quiroga, J. Antoni, Schillinger, Arild, Skutle, Arvid, Verspreet, Sofie, van den Brink, Wim, Schoevers, Robert A., Addiction, Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study, Psychiatry and Mental health, Medicine (miscellaneous) |
| title | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_full | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_fullStr | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_full_unstemmed | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_short | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| title_sort | psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <scp>iasp</scp> study |
| title_unstemmed | Psychiatric comorbidity in treatment‐seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study |
| topic | Psychiatry and Mental health, Medicine (miscellaneous) |
| url | http://dx.doi.org/10.1111/add.12370 |